EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Teneurin C-terminal associated peptide (TCAP)-1 attenuates the development and expression of naloxone-precipitated morphine withdrawal in male Swiss Webster mice

Lauren E Mueller, Roseanne S Wexler, David A Lovejoy, Robert B Stein, Andrew M Slee

Psychopharmacology · 2024

DOI: 10.1007/s00213-024-06582-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychopharmacology, 2024. Verfasst von Lauren E Mueller und 4 weiteren Autor:innen. Beteiligte Einrichtung: Protagenic Therapeutics, Inc., New York, NY, USA. Hauptthemen laut MEDLINE: Substance Withdrawal Syndrome, Naloxone, Narcotic Antagonists, Morphine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Corticotropin-releasing factor (CRF), the apical stress-inducing hormone, exacerbates stress and addictive behaviors. TCAP-1 is a peptide that directly inhibits both CRF-mediated stress and addiction-related behaviors; however, the direct action of TCAP-1 on morphine withdrawal-associated behaviors has not previously been examined.

Objective

To determine whether TCAP-1 administration attenuates behavioral and physiological consequences of morphine withdrawal in mice.

Methods

Mice were administered via subcutaneous route TCAP-1 either before or after initial morphine exposure, after which jumping behavior was quantified to assess the effects of TCAP-1 on naloxone-precipitated morphine withdrawal. As a comparison, mice were treated with nonpeptide CRF 1 receptor antagonist CP-154,526. In one experiment, plasma corticosterone (CORT) was also measured as a physiological stress indicator.

Results

Pretreatment with TCAP-1 (10–250 nmol/kg) before morphine treatment significantly inhibited the development of naloxone-precipitated withdrawal. TCAP-1 (250–500 nmol/kg) treatment administered after morphine treatment attenuated the behavioral expression of naloxone-precipitated withdrawal. TCAP-1 (250 nmol/kg) treatment during morphine treatment was more effective than the optimal dosing of CP-154,526 (20 mg/kg) at suppressing the behavioral expression of naloxone-precipitated withdrawal, despite similar reduction of withdrawal-induced plasma CORT level increases.

Conclusions

These findings establish TCAP-1 as a potential therapeutic candidate for the prevention and treatment of morphine withdrawal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance Withdrawal SyndromeNaloxoneNarcotic AntagonistsMorphineCorticosteroneAnimalsMaleMiceDose-Response Relationship, DrugPyrrolesNerve Tissue ProteinsReceptors, Corticotropin-Releasing HormoneBehavior, AnimalMorphine DependencePyrrolidinesInjections, SubcutaneousCorticotropin-Releasing HormonePyrimidinesCRF Receptor, Type 1

Stichwörter der Autor:innen

CorticosteroneCorticotropin-releasing factorMiceMorphine withdrawalTeneurin C-terminal associated peptide-1

Substanzen

NaloxoneNarcotic AntagonistsMorphineCorticosteroneCP 154526TCAP-1 protein, mousePyrrolesNerve Tissue ProteinsReceptors, Corticotropin-Releasing HormoneCRF Receptor, Type 1

Autor:innen und Institutionen

  • Protagenic Therapeutics, Inc., New York, NY, USA.
  • NeoSome Life Sciences, Lexington, MA, USA.
  • Department of Cell and Systems Biology, University of Toronto, Toronto, CA, Canada.
  • Protagenic Therapeutics, Inc., New York, NY, USA. Andrew.Slee@Protagenic.com.

Zitieren

APA

Mueller, L. E., Wexler, R. S., Lovejoy, D. A., Stein, R. B., & Slee, A. M. (2024). Teneurin C-terminal associated peptide (TCAP)-1 attenuates the development and expression of naloxone-precipitated morphine withdrawal in male Swiss Webster mice. Psychopharmacology. https://doi.org/10.1007/s00213-024-06582-0

Vancouver

Mueller LE, Wexler RS, Lovejoy DA, Stein RB, Slee AM. Teneurin C-terminal associated peptide (TCAP)-1 attenuates the development and expression of naloxone-precipitated morphine withdrawal in male Swiss Webster mice. Psychopharmacology. 2024. doi:10.1007/s00213-024-06582-0

BibTeX
@article{Mueller2024,
  author = {Mueller, Lauren E and Wexler, Roseanne S and Lovejoy, David A and Stein, Robert B and Slee, Andrew M},
  title = {Teneurin C-terminal associated peptide (TCAP)-1 attenuates the development and expression of naloxone-precipitated morphine withdrawal in male Swiss Webster mice},
  journal = {Psychopharmacology},
  year = {2024},
  doi = {10.1007/s00213-024-06582-0}
}
Kostenlos starten →